The Glycated Haemoglobin Testing Market Forecast and Growth Trends offer a forward-looking assessment of diagnostic innovations reshaping diabetes management. Global Glycated Haemoglobin Testing Market Industry size expanded 7.5% year-on-year in 2024 as advances in assay automation and digital analytics improved throughput in both clinical laboratories and point-of-care settings. Rising global diabetes prevalence—reaching 537 million diagnosed cases in 2024—alongside evolving reimbursement frameworks underpin strong business growth and shifting market dynamics, delivering critical market insights for stakeholders exploring long-term market opportunities.
The glycated haemoglobin testing market is estimated to be valued at USD 260.0 Mn in 2025 and is expected to reach USD 469.2 Mn by 2032, growing at a compound annual growth rate (CAGR) of 8.8% from 2025 to 2032.
Market Size and Overview
The Global Glycated Haemoglobin Testing Market size is estimated to be valued at USD 260.0 Mn in 2025 and is expected to reach USD 469.2 Mn by 2032, exhibiting a compound annual growth rate (CAGR) of 8.8% from 2025 to 2032. Market size, market report, and market analysis data from recent surveys show steady demand growth for both point-of-care and high-throughput lab-based A1C assays. The market forecast further suggests that enhanced reimbursement policies in North America and Europe will drive expansion, while Asia Pacific offers untapped market opportunities due to rising healthcare investments and increased testing awareness.
Market Segments
In terms of market segments, the Glycated Haemoglobin Testing Market is categorized by product type, test type, and end user. Under product type, lab-based systems and point-of-care devices are sub-segments; lab-based systems remained dominant in 2024 with over USD 110 Mn revenue due to high-throughput workflows, while point-of-care devices emerged as the fastest-growing segment, posting a 12% year-on-year increase in 2025 driven by home diagnostics. By test type, the sub-segments include high-performance liquid chromatography (HPLC), immunoassay, and enzymatic assays, with HPLC leading 2024 performance at USD 95 Mn and immunoassay kits expanding 14% in 2025 thanks to automation gains. The end user categories—hospitals, diagnostic centers, and home care—saw hospitals hold the largest market share and industry share in 2024, while home care testing surged 15% in 2025 supported by direct-to-consumer kit launches. These sub-segments illustrate the extensive market scope across healthcare settings.
Market Drivers
A principal market driver is the rising global diabetes burden combined with strengthened diagnostic reimbursement. According to market research and the Glycated Haemoglobin Testing Market report released in 2024, government initiatives in 25 countries expanded A1C test coverage by 18% year-on-year, reducing out-of-pocket costs and fueling demand. Innovators introduced cost-effective enzymatic assays in 2025 that lowered per-test pricing by 10%, addressing key market challenges such as affordability and accessibility. These developments drive market expansion and mitigate market restraints such as high per-test costs, highlighting how policy shifts and product-level advancements shape future market dynamics.
Segment Analysis
Focusing on the product type segment, point-of-care devices have demonstrated robust growth compared to lab-based systems. In 2025, Glycated Haemoglobin Testing Market revenue for these devices surpassed USD 45 Mn, up from USD 33 Mn in 2024, reflecting a 36% increase. Case studies show that Abbott Laboratories’ 2025 launch of a compact POC HbA1c analyzer enabled community clinics to cut result turnaround times by 50%, boosting testing throughput. The convenience of decentralized testing, coupled with advances in miniaturized optics and software integration, underpins the shift toward point-of-care solutions over traditional lab platforms.
Consumer Behaviour Insights
End users exhibited notable behavioural shifts in 2024–2025, reflecting growing digital adoption and cost awareness. Firstly, 42% of diabetic patients accessed test results via online portals by mid-2025, a 25% rise over 2024, underscoring increased digital consumption habits. Secondly, pricing sensitivity pushed 30% of clinics to switch from high-cost HPLC assays to enzymatic alternatives in 2025, demonstrating market opportunities for cost-efficient offerings. Thirdly, sustainability preferences emerged, with 20% of diagnostic centers opting for carbon-neutral kit packaging in late 2025. Emerging Glycated Haemoglobin Testing Market trends reveal these evolving consumer decision-making patterns and industry trends.
Key Players
Key players active in this domain include:
1. Abbott Laboratories
2. Roche Diagnostics
3. Siemens Healthineers
4. Tosoh Corporation
5. Bio-Rad Laboratories
6. Arkray Inc.
7. EKF Diagnostics
8. DiaSys
9. Sinocare Inc.
10. Helena Laboratories
11. Werfen
12. Trinity Biotech
Recent Glycated Haemoglobin Testing Market share dynamics remained stable in 2024, indicating minimal shifts among the top five companies. In 2024, Roche Diagnostics expanded immunoassay production in Switzerland, boosting throughput by 20%. In 2025, Abbott Laboratories launched an integrated point-of-care HbA1c system, driving a 15% increase in US market revenue. Siemens Healthineers’s Southeast Asia entry via regional distributor partnerships in 2025 generated a 10% uplift in orders—underscoring strategic regional expansion and market growth strategies.
Key Winning Strategies
Innovative strategies have set certain players apart. In 2025, Roche Diagnostics integrated AI-powered analytics into its HbA1c assay platform, reducing result interpretation time by 30% and elevating lab efficiency. Siemens Healthineers pioneered a cloud-based remote monitoring ecosystem in 2024, enabling real-time device calibration and reducing downtime by 25%. Tosoh Corporation rolled out direct-to-consumer test kits in Japan in 2025, capturing a 12% share of the home-testing market. These differentiated approaches illustrate how advanced digital integration and consumer-centric models drive business growth and deliver competitive advantage.
FAQs
1. Who are the dominant players in the Glycated Haemoglobin Testing Market?
Dominant players include Abbott Laboratories, Roche Diagnostics, and Siemens Healthineers, each leading through product innovation and targeted regional expansion.
2. What will be the size of the Glycated Haemoglobin Testing Market in the coming years?
The market is projected to grow from USD 260.0 Mn in 2025 to USD 469.2 Mn by 2032, at a CAGR of 8.8%.
3. Which end-user industry has the largest growth opportunity?
The home care segment offers the largest growth opportunity, with direct-to-consumer kits recording 15% expansion in 2025.
4. How will market development trends evolve over the next five years?
Future trends include AI-driven analytics, decentralized testing, and eco-friendly consumables, reflecting shifts toward digital integration and sustainability.
5. What is the nature of the competitive landscape and challenges in the Glycated Haemoglobin Testing Market?
The landscape is moderately consolidated, with intense innovation and pricing pressures; key challenges include regulatory alignment and cost containment.
6. What go-to-market strategies are commonly adopted in the Glycated Haemoglobin Testing Market?
Common strategies include regional partnerships, direct-to-consumer kit launches, and AI-enabled product enhancements to accelerate adoption and market penetration.
Get more insights on: Glycated Haemoglobin Testing Market
Get this Report in Japanese Language: グリコヘモグロビン検査市場
Get this Report in Korean Language: 당화혈색소검사시장
Get more related Articles on: Advances in Hemophilia Treatment in the United States Over the Past Few Decades
About Author:
Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. (https://www.linkedin.com/in/ravina-pandya-1a3984191__
Comments
0 comment